Researchers examined whether adjunctive gabapentin or memantine and standard treatment with a selective serotonin-reuptake inhibitor (SSRI) might lead to further improvements in patients with OCD.
A brain stimulation device to treat OCD has received approval for marketing by the US Food and Drug Administration.
These results identify several predictive factors for remission in children with OCD and may be useful for clinicians in tailoring their treatment approach, although the impact of adjunctive d-cycloserine requires further investigation.
Family history of OCD and the presence of tics may be important considerations for initial choice of treatment.
The risk of any mental disorder was increased for individuals with a positive streptococcal test, especially for OCD and tic disorders
DCS shows a small augmentation effect on exposure-based therapy.
Despite intense research efforts and recent advances in understanding the condition, the exact etiology of OCD remains largely undefined.
Sign Up for Free e-newsletters
Psychiatry Advisor Articles
- Methylphenidate for ADHD Treatment May Be Associated With Low BMI
- Patients With Schizophrenia May Benefit From Occupational Therapy
- Minocycline vs Routine Care for Clinical Symptom Improvement in Schizophrenia
- Temperament Traits May Predict Treatment Outcomes Depression
- Psychiatric Screening Tool for EMS Aims to Reduce Emergency Department Burden
- Oral Therapy for Suicidal Bipolar Depression Gets Breakthrough Designation
- Psychotic Experiences Linked to Anxiety and Somatic Symptoms in Preadolescent
- DSM-5 Anxious Distress Specifier Valid for Major Depressive Disorder
- Social Stigma Worsens Mental Health With Autism
- Onset of Psychosis Not Related to Cognitive Deterioration in Schizophrenia